CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This phase II trial is studying how well CCI-779 works in treating patients with relapsed or refractory chronic lymphocytic leukemia. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop cancer cells from dividing so they stop growing or die

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• Diagnosis of chronic lymphocytic leukemia (CLL)

• Relapsed, refractory, or transformed disease

• Relapsed disease defined as symptomatic loss of a prior partial or complete response to a regimen containing a purine analog and/or a monoclonal antibody AND evidence of disease progression

• Primary resistant disease defined as failure to achieve an objective response to a regimen containing a purine analog and/or a monoclonal antibody

• Transformed CLL (Richters transformation), must meet both of the following criteria:

• Histologically confirmed lymphoma

• Measurable disease

• No CNS disease

• Performance status - ECOG 0-2

• Bilirubin ≤ 2 mg/dL (unless elevated due to Gilbert's disease)

• SGOT and SGPT < 3 times upper limit of normal

• Creatinine ≤ 2 mg/dL (unless due to organ leukemic involvement)

• No symptomatic congestive heart failure

• No unstable angina pectoris

• No cardiac arrhythmia

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• HIV-positive patients allowed provide CD4 counts are normal and no AIDS-defining disease is present

• No history of allergic reactions attributed to compounds of similar chemical or biological composition to CCI-779

• No ongoing or active infection

• No psychiatric illness or social situation that would preclude study compliance

• No other concurrent uncontrolled illness

• See Disease Characteristics

• No concurrent prophylactic hematopoietic colony-stimulating factors

• See Disease Characteristics

• More than 2 weeks since prior cytotoxic chemotherapy and recovered

• More than 2 weeks since prior radiotherapy and recovered

• No other concurrent investigational or antitumor agents

• No other concurrent cytotoxic agents

• No concurrent combination antiretroviral therapy for HIV-positive patients